


ANTIBODY DRUG DISCOVERY

A BIL

ONE-STOP INTEGRATED SERVICE

- Comprehensive biology capability for target validation
- Integrated multiple platforms supporting reagent generation, assay development, and bioanalytical analysis
- · Featured B cell cloning, hybridoma, and phage display technology for antibody lead candidate generation
- Strong antibody engineering asset for candidate optimization
- Built-in manufacturability assessment connecting discovery to CMC development
- Extensive experience in managing and delivering over 60 integrated service projects successfully


INTEGRATED PROJECT FLOW CHART



CASE STUDY


PHASE I - ANTIBODY LEAD CANDIDATE GENERATION

- Both hybridoma and phage display platforms for antibody generation
- · Functional assays developed and adapted for early screening to identify potential functional candidates



CASE STUDY

PHASE II - ANTIBODY ENGINEERING AND CANDIDATE SELECTION



LEARN MORE AT CHEMPARTNER.COM/SERVICES/BIOLOGICS-DISCOVERY/ANTIBODY-DISCOVERY/